IMBiologics Corp
493280
Company Profile
Business description
IMBiologics Corp is a next-generation biopharmaceutical company developing antibody therapeutics. Its proprietary IM-OpDECon platform enables the design of differentiated biologics targeting autoimmune diseases and immuno-oncology. The group leverages diverse antibody modalities to tackle critical unmet medical needs beyond the reach of current therapies. Its business areas are Antibody Research & Development and Autoimmune Diseases Immuno-Oncology. The group's pipeline products are IMB-101/102, IMB-201, and IMB-402.
Contact
260 Changnyong-daero
11th Floor, Gwanggyo Central Biz Tower
Yeongtong-gu, Iui-dong
Gyeonggi-do
Suwon-si
KORT: +82 3180678170
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
Employees
Stocks News & Analysis
stocks
Undervalued ASX share retains wide moat rating despite regulatory pressures
Proposed price regulation impacts our fair value.
stocks
Our top ASX picks in every sector
These companies are our favourite choices for investors wanting to boost Aussie equity exposure.
stocks
Tesla: Shares fall as deliveries come in below consensus
Long-term growth less reliant on auto sales.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,165.70 | 2.00 | 0.02% |
| CAC 40 | 8,272.15 | 363.41 | 4.60% |
| DAX 40 | 24,017.31 | 1,095.72 | 4.78% |
| Dow JONES (US) | 47,912.97 | 1,328.51 | 2.85% |
| FTSE 100 | 10,620.36 | 271.57 | 2.62% |
| HKSE | 25,893.02 | 776.49 | 3.09% |
| NASDAQ | 22,687.83 | 669.98 | 3.04% |
| Nikkei 225 | 56,308.42 | 2,878.86 | 5.39% |
| NZX 50 Index | 13,253.94 | 184.28 | 1.41% |
| S&P 500 | 6,776.33 | 159.48 | 2.41% |
| S&P/ASX 200 | 8,951.80 | 21.00 | -0.23% |
| SSE Composite Index | 3,995.00 | 104.83 | 2.69% |